A Chronic Obstructive Pulmonary Disease (COPD) Trial Investigating Roflumilast on Safety and Effectiveness in China, Hong Kong and Singapore:

NCT01313494 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

626

Enrollment

INDUSTRY

Sponsor class

Conditions

COPD

Interventions

DRUG: Roflumilast
DRUG: Placebo
DRUG: Salbutamol

Sponsor

AstraZeneca